OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company
OneMedNet Corporation reported a mid six-figure re-order from a company developing radiology foundation models.
Stocks · News reference
OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook
OneMedNet Corporation announced preliminary third-quarter 2026 revenue of approximately $1 million and provided revenue guidance for the fourth quarter of 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
OneMedNet Receives High Six-Figure Add-On Order Under Multiyear Agreement
OneMedNet Corporation has secured a high six-figure add-on order from a precision medicine customer, exercising an expansion option that increases data volume by 150%.
OneMedNet Enters Its 12th Channel Partner Agreement With A Global Pharmaceutical Intelligence And Data Solutions Provider To Distribute Its Clinical Data; Terms Not Disclosed
The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach
OneMedNet Announces Addition Of Hospital Systems To Its iRWD Platform, Intends To Expand Network By Up To 12 Additional Hospitals
OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven
OneMedNet Announces Initial One-Year Korea Distribution Agreement With Mediplexus For Its U.S. Healthcare Data; Terms Not Disclosed
OneMedNet shares are trading higher after the company announced a seven-figure multi-year agreement to deliver de-identified, multimodal, longitudinal clinical Real World Data to a commercially scaled AI-enabled precision medicine company.